Executive Team

Paul J. Diaz, was named president, chief executive officer and member of the Myriad Genetics board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses.
Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine.

Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the federation of American Hospitals, and the Bloomberg School of Public Health at Johns Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.

Maggie Ancona, senior vice president, Transformation and Chief of Staff to the CEO, joined Myriad Genetics in January 2021. Previously, she led Global Transformation and Program Management at Hewlett Packard (HP) and Dell Technologies where she oversaw business transformation strategy, executed large-scale programs and cost management efforts, while retooling digital infrastructure for the future. Mrs. Ancona received a bachelor’s degree in English from the University of San Francisco.

Patrick Burke was promoted to EVP of Strategy and Innovation in May 2021, responsible for corporate development, Myriad’s companion diagnostics business, digital strategy and partnerships with large health systems and health care providers. In addition to these functions, he leads the executive strategy team and the development long term corporate strategy. Dr. Burke joined Myriad in 2001 and has more than 20 years of experience in the precision medicine and pharmaceutical industries. He received his PhD in Experimental Cell Biology from the University of Utah, School of Medicine and his BA in Molecular Biology from the University of California, San Diego.

Jennifer Fox, Chief Legal Officer, joined Myriad Genetics in September 2024. Prior to joining Myriad Genetics, she worked as the Executive Vice President of External Affairs for Emergent BioSolutions where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she held positions with Brinks, Gilson & Lione, Novozymes North America and GSK. She earned a Bachelor of Science in Biology from the University of Toledo, a Master of Science in Biochemistry also from the University of Toledo, and a J.D. from North Carolina Central University.

Kevin R. Haas, chief technology officer, joined Myriad Genetics in May 2013. Previously, he was vice president of Bioinformatics. Dr. Haas also serves on the Board of Directors and is vice president for USA Triathlon, the non-profit national governing body for the sport. Dr. Haas received a B.S. from University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics from single molecule fluoresce. He has co-authored 16 peer reviewed publications and eight patent applications.

Scott Leffler is Myriad’s chief financial officer, focusing on leading the company’s financial team and strategy to advance Myriad’s long-term growth and profitability.

He joined Myriad in January 2024, bringing nearly 20 years of finance experience across a broad range of healthcare and payer market segments at public and private equity-backed companies, with expertise in finance transformation, acquisitions and integrations, and risk management.

Before joining Myriad, he was the CFO of Clover Health. Prior to Clover Health, he was CFO and Treasurer at Sotera Health.

He earned his B.A. in economics and history from Yale University and an M.B.A. from Emory University.

Dale Muzzey, Ph.D., is chief scientific officer of Myriad Genetics. He joined the company in April 2014. Previously, he was senior vice president of R&D. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B.A. with honors in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.

Sam Raha is Myriad’s chief operating officer, focusing on driving profitable growth by strengthening operations and customer experience, including the patient and provider journey and product innovations.

He joined Myriad in December 2023, bringing over twenty-five years of proven experience in the life sciences and diagnostics industry, including in general management roles leading research and development, operations, and commercial teams.

Before joining Myriad, he was the president of Agilent’s Diagnostics and Genomics Group with overall responsibility for strategy, along with business and financial results. Prior to Agilent, he was vice president of global marketing at Illumina, with responsibility for leading the company’s overall marketing function, including product management and corporate marketing.

Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.

Shereen Solaiman, chief people officer, joined Myriad Genetics in March 2023. She has more than twenty years of professional experience in the human resources field. Before joining Myriad, she was senior vice president and chief human resources officer at OhioHealth, where she drove business results through talent development at all levels. Shereen received her master’s degree in Public Administration from New York University and her bachelor’s degree in Journalism/Public Relations from Ohio University.

Mark Verratti was promoted to chief commercial officer of Myriad Genetics in April 2022, responsible for accelerating the enterprise growth team to enhance commercial and marketing capabilities, gain new customer insights, and enhance demand generation. In addition to his expanded enterprise role, he also continues to oversee Myriad’s Mental Health business, including the GeneSight® pharmacogenomics test. Mr. Verratti has more than 20 years of experience leading large commercial organizations in the pharmaceutical and medical device industries. He has held senior and general management positions with Cyberonics/LivaNova leading teams in over 70 countries. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.